SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

zodasiran

ARWR·ARROWHEAD PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If the Phase 3 YOSEMITE trial succeeds, an NDA submission could follow in late 2027 or 2028, with potential FDA approval in 2028 or later. The timeline depends on the duration of the treatment and follow-up period in the HoFH study.
Why 4/10
The next hard binary catalyst is the topline data readout from the Phase 3 YOSEMITE study in HoFH. Enrollment completed in July 2026, and with a typical treatment period likely of 24-48 weeks in an ultra-rare disease, data is expected no earlier than late 2027, beyond the 12-month window. ImpactScore is 4 (default) because there is no dated binary catalyst within roughly 12 months, the drug is in mid-to-late-stage development but not yet filed/approved, and Arrowhead has other pipeline assets including the already-approved REDEMPLO.
Actionable Insight NEUTRAL

The next major catalyst for zodasiran is the topline data readout from the Phase 3 YOSEMITE study in HoFH. Enrollment was completed in July 2026; a 24- to 48-week treatment period would likely push data into the second half of 2027 or 2028. Positive results would set up an NDA filing for an ultra-rare indication with a clear path to market, while negative or modest results would undermine the asset's thesis given that evinacumab already exists as an approved ANGPTL3-directed therapy.

Price Chart

Loading chart...

Executive Summary

Zodasiran (formerly ARO-ANG3) is Arrowhead Pharmaceuticals' investigational RNAi therapeutic targeting ANGPTL3, a liver protein that regulates fat metabolism. Phase 2b data published in the New England Journal of Medicine showed substantial reductions in triglycerides and LDL cholesterol with a favorable safety profile. The drug is currently in Phase 3 development, with the YOSEMITE study in homozygous familial hypercholesterolemia (HoFH) completing enrollment in July 2026 and a Phase 3 SPRUCE study in adolescents. While zodasiran addresses a clear unmet need in an ultra-rare disease, it faces competition from evinacumab (Evkeeza), an already-approved ANGPTL3 antibody. The next binary catalyst is the YOSEMITE topline readout, likely more than 12 months out.

How It Works

Zodasiran is an RNA interference (RNAi) therapeutic that silences the gene responsible for producing a liver protein called ANGPTL3. By reducing ANGPTL3 levels, the drug allows the body to more effectively break down fats in the blood, lowering triglycerides and LDL cholesterol (bad cholesterol). It is given as a subcutaneous injection (under the skin).

Trial Status

Phase 3 YOSEMITE study in HoFH completed enrollment in July 2026 (first patient dosed July 2025). Topline data not yet reported. A separate Phase 3 SPRUCE study in adolescents with HoFH is also underway. Phase 2b ARCHES-2 study in mixed hyperlipidemia completed with results published in NEJM (May 2024). Phase 2 GATEWAY study in HoFH has reported preliminary data.

The Two-Sided Case

▲ Bull Case1
Phase 2b ARCHES-2 data in mixed hyperlipidemia, published in the New England Journal of Medicine, showed zodasiran produced robust reductions in triglycerides (up to 59%), LDL-C (up to 32%), and ANGPTL3 (up to 71%) with a favorable safety profile. Zodasiran is a subcutaneously injected RNAi therapeutic, which could offer dosing convenience over evinacumab's IV infusion regimen and potentially capture share in the HoFH market. Arrowhead has a strong analyst consensus (20 Buy/Strong Buy vs 1 Hold, mean price target $106 vs $47.78 current price) with multiple firms reiterating Buy ratings after the November 2026 earnings. The YOSEMITE Phase 3 study completed enrollment in under 13 months, suggesting robust investigator and patient interest in an ultra-rare disease with high unmet need.
▼ Bear Case1
Evinacumab (Evkeeza), a monoclonal antibody targeting ANGPTL3, is already approved for HoFH in adults, adolescents, and children as young as one year, giving zodasiran a significant commercial disadvantage in an ultra-rare market. Phase 3 YOSEMITE readout is likely more than 12 months away (enrollment completed July 2026), leaving no near-term binary catalyst to drive the stock. Arrowhead shares fell ~15% in November 2026 after rival Ionis cut its Tryngolza forecast, signaling concern about the broader severe hypertriglyceridemia market that could also affect how investors view zodasiran's commercial prospects. Multiple institutional holders trimmed or exited ARWR in Q3 2026, and two directors sold shares in August 2026 above $86, well above the current ~$48 price.

Upcoming Catalysts

  • Phase 3 YOSEMITE topline data readout in HoFH (estimated ~2027-2028)
  • Phase 3 SPRUCE study updates in adolescent HoFH
  • Potential Phase 3 initiation in mixed hyperlipidemia following ARCHES-2 results

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARROWHEAD PHARMACEUTICALS, INC. 8-K ARWR ·Originating report

Sources · 7

Hover a chip for the title
1 businesswire.com2 morningstar.com3 nejm.org4 markets.financialcontent.com5 mx.ibtimes.com6 ajmc.com7 markets.financialcontent.com